Table 14.

Results of Univariate and Multivariate Analyses for Major Morbidity in Survivors to Discharge

Variable
(All Yes/No
Unless Stated)
(n)Severe Scan AbnormalityTreated Retinopathy of PrematuritySupplemental Oxygen at 40 Weeks' PMA
Univariate
(n = 314)
OR (95% CI)
Multivariate
(n = 306)
OR (95% CI)
Univariate
(n = 309)
OR (95% CI)
Multivariate (n = 309)
OR (95% CI)
Univariate
(n = 314)
OR (95% CI)
Multivariate
(n = 283)
OR (95% CI)
Known at birth
Gestation (per wk)(314).78 (.53–1.17).59 (.39–.91)*.53 (.34–.84)*.50 (.35–.70)c.57 (.37–.86)*
Birth weight (per 100 g)(314).99 (.77–1.29)1.00.72 (.59–.89)b
Birth weight ratio(314)1.13 (.84–1.52).70 (.52–.93)*.81 (.64–1.01)
Multiple(314).85 (.42–1.69).50 (.21–1.18)1.45 (.87–2.44)
Male sex(314).81 (.45–1.46).71 (.37–1.34)1.51 (.97–2.35)2.31 (1.35–3.93)**
Any obstetric problems(314).49 (.27–.90)*(1.49–8.07)*1.35 (.85–2.16)
  Preeclampsia(312)1.65 (.32–8.4)1.98 (.39–10.2).94 (.23–3.81)
  PROM(312).48 (.22–1.04).87 (.42–1.81)1.18 (.72–1.95)
  Cervical suture(312).93 (.34–2.55)1.53 (.59–3.97)1.00 (.48–2.1)
  APH(312)1.01 (.51–2.01)2.69 (1.39–5.21)**1.13 (.67–1.90)
  Chorioamnionitis(312).50 (.22–1.1).98 (.47–2.05).92 (.55–1.54)
Antenatal steroid(313).90 (.44–1.82).71 (.34–1.47)1.16 (.67–2.00)
Steroid >24 h before birth(313).39 (.21–.73)**.39 (.20–.77)**1.00 (.54–1.90)1.25 (.80–1.94)
Tocolytics(308)1.51 (.81–2.8)2.02 (1.04–3.94)*.71 (.34–1.09)1.74 (1.06–2.84)*2.53 (1.42–4.51)**
Maternal age (per y)(313)1.00 (.95–1.05)1.03 (.98–1.09).98 (.94–1.01).95 (.91–1.00)*
Ethnic group = black(314).42 (.15–1.24).12 (.02–.81)*.09 (.01–.69)*.94 (.50–1.76)
Postnatal variables
 Vaginal delivery(314).63 (.25–1.56)1.03 (.43–2.47).94 (.51–1.72)
 HR at 5 min, <100 bpm(314).81 (.23–2.85).98 (.28–3.46)1.05 (.43–2.54)
 Admission temperature, ≥35°C(298)1.00 (.50–2.00).68 (.33–1.40).40 (.23–.69)14-165.50 (.27–.96)*
 CRIB score8 (per point)(296)1.07 (.98–1.16)1.07 (.97–1.19)1.17 (1.09–1.26)14-1651.12 (1.03–1.22)*
 Postnatal transfer(314)3.06 (1.44–6.46)**2.61 (1.20–5.71)*1.38 (.57–3.35)1.47 (.76–2.84)
 Surfactant therapy(314)1.42 (.57–3.54).75 (.32–1.75)3.13 (1.58–6.21)14-1653.20 (1.42–7.23)**
  • * P ≤ .05;

  • ** P ≤ .001; and

  • F14-165 P ≤ .0001.

    OR indicates odds ratio of developing condition; APH, antepartum hemorrhage.